Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Interventional Therapy in Hepatobiliary Diseases | Dr. Xuefeng Luo: In-depth Analysis of the French Guidelines on Transjugular Intrahepatic Portosyste

    Interventional therapy is an emerging clinical discipline and an important part of minimally invasive medicine. It stands as the third major clinical discipline, distinct from traditional internal medicine and surgery. Interventional therapy allows the treatment of various diseases through tiny channels a few millimeters in diameter created in the skin, using advanced imaging technologies such…

    2024.09.04
  • Dynamic Changes in Circulating Tumor DNA in Hepatocellular Carcinoma Patients Reveal Its Potential as a Non-Invasive Biomarker

    A recent clinical study conducted by Dr. Jean-Charles Nault and his team at the Cordeliers Research Center of Sorbonne University, France, was published in Gut journal. This study reveals the dynamic changes in circulating tumor DNA (ctDNA) in patients with hepatocellular carcinoma (HCC) and its clinical significance. The findings provide new perspectives and tools for…

    2024.09.04
  • Newly Released! IDSA 2024 Guidelines for Treating Resistant Gram-Negative Bacterial Infections

    As antimicrobial resistance (AMR) continues to be a growing global public health challenge, treating infections caused by resistant bacteria has become increasingly difficult. Recently, the Infectious Diseases Society of America (IDSA) released the “IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections,” providing clinicians with valuable treatment recommendations. This document primarily addresses infections…

    2024.09.04
  • Dr. Steven Narod: Bilateral Mastectomy and Breast Cancer Mortality—A Rethink of Clinical Guidelines

    In recent years, bilateral mastectomy, as a surgical approach to prevent contralateral breast cancer, has gained a certain degree of attention and application. However, there is still controversy regarding the actual effectiveness of bilateral mastectomy in preventing breast cancer mortality. Recently, Dr. Steven Narod from the Dalla Lana School of Public Health published a research…

    2024.09.04
  • International Perspective丨Weighing the Risks of Chemotherapy: Is Chemotherapy Necessary for Adjuvant and Stage IV NSCLC Treatment?

    The necessity of adding chemotherapy to postoperative adjuvant treatment and in Stage IV non-small cell lung cancer (NSCLC) remains a topic of debate. In this article, Dr. Mark G. Kris from Memorial Sloan Kettering Cancer Center analyzes the value of chemotherapy in the adjuvant treatment of early-stage NSCLC with EGFR and ALK mutations, as well…

    2024.09.03
  • International Perspective丨What Challenges Does Immunotherapy Face in Early-Stage NSCLC?

    The successes of immunotherapy and targeted therapy in metastatic non-small cell lung cancer (NSCLC) have raised hopes for implementing these therapies in earlier stages of the disease. Recent trial results indicate that neoadjuvant, adjuvant, and perioperative immunotherapy may improve the cure rates of early-stage NSCLC. While early diagnosis of patients could make immunotherapy a significant…

    2024.09.03
  • Lung Cancer Frontline丨Dr. Cho Discusses the Impact of the CHRYSALIS-2 Cohort C Study on the Treatment of Atypical EGFR-Mutant Lung Cancer

    The CHRYSALIS-2 study (NCT04077463) Cohort C investigated the combination of amivantamab and lazertinib for the treatment of patients with atypical EGFR-mutant non-small cell lung cancer (NSCLC). The study enrolled patients with various EGFR mutations who were either treatment-naive or had received limited prior treatment. The results demonstrated that the amivantamab+lazertinib combination showed promising antitumor activity,…

    2024.09.03
  • International Lung Cancer Academic Conference | Dr. Chunxue Bai: Lung Cancer Screening and Management in the Metaverse Era

    In 2022, Dr. Chunxue Bai from Fudan University Shanghai Cancer Center, introduced the concept of “Metaverse Medicine,” aiming to leverage metaverse technology to revolutionize disease prevention and treatment. At the 2024 International Lung Cancer Academic Conference, Professor Bai presented a report titled “Lung Cancer Screening and Management in the Metaverse Era.” This article provides a…

    2024.09.03
«previous next»
Recent Posts
  • Personalized mRNA Vaccine Plus Pembrolizumab Reduces Recurrence and Metastasis in Melanoma
  • ESMO Preview | Professor Huihui Li: Iza-bren Ushers in a New Era of Bispecific Antibody–Drug Conjugate Therapy for Breast Cancer
  • ESMO Preview | Professor Fan Wu: From Breakthrough to Transformation—How Iza-bren Is Reshaping Breast Cancer Treatment and Ushering in a New Era of Bispecific ADC Therapy
  • ESMO Preview | Professor Jiong Wu: China-Originated Innovation Goes Global—Izalontamab Brengitecan Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer
  • 2026 Xianghu Breast Cancer Treatment Frontiers Conference | Professor Zhanhong Chen: Cardio-Oncology Supports Comprehensive Breast Cancer Care, While ADCs Reshape Treatment for Advanced HER2-Positive Disease
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top